So far, the results are contrasting: in a metastatic renal cell carcinoma higher level of sPD-L1 is associated with longer progression-free survival,8 but on the other hand, studies regarding a non-small cell lung carcinoma and a melanoma indicate worse treatment outcomes for patients with high expression of sPD-L1.9, 10, 11. Here, SPDL1 is linked to melanoma.